
by PLT Health Solutions · plthealth.com
Sign in to send a request. Suppliers are told your name, company, role and country.
5-Loxin® by PLT Health Solutions is a patented extract of Boswellia serrata, standardized to 30% 3-O-acetyl-11-keto-ß-boswellic acid (AKBA). Supported by over 15 studies, including human clinical trials, it delivers efficacy in joint comfort and flexibility beginning at 100 mg/day. This low-dose, vegan, gluten-free, non-GMO, Halal, and Kosher certified ingredient positively influences biological markers associated with inflammation. With proven stability across formulations, 5-Loxin® is ideal for bone, joint, and healthy aging applications.
Reproduced exactly as the manufacturer states them. A parameter the catalogue does not hold shows as a dash rather than a default.
| Parameter | Value |
|---|---|
| Active compound | 3-O-acetyl-11-keto-ß-boswellic acid (AKBA) |
| Physical form | Oil · Powder |
| Marker | Guaranteed level | Applies to | Test method |
|---|---|---|---|
| akba | min. 30 % | - | - |
| Parameter | Value |
|---|---|
| Dosage studied | 100 mg |
Formats the supplier has run at commercial scale. No inclusion levels have been supplied for this listing yet.
Boswellia, curcumin, collagen peptides and MSM all sell into joint formulations and behave nothing alike on a production line. A tour of the mechanisms, the specification traps, and where the real formulation constraints sit.
“Standardized to 95%” is four words doing at least three different jobs. What the marker, the minimum and the missing test method each tell you — and what none of them do.
Sign in to send a request. Suppliers are told your name, company, role and country.